Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2026-01-24 @ 6:37 AM
Study NCT ID:
NCT01047358
Status:
COMPLETED
Last Update Posted:
2015-10-08
First Post:
2009-12-24
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
Sponsor:
Pfizer
Organization:
Study Overview
Official Title:
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This non-interventional study is to monitor use in real practice in Korea including adverse events on Aromasin (Exemestane).
Detailed Description:
All cases at the participating institutions.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: